Can-fite Biopharma Says Its Veterinary Partner Vetbiolix Reported Positive Results In An Osteoarthritis Multicenter Clinical Study In Dogs Treated With Piclidenoson
Portfolio Pulse from Benzinga Newsdesk
Can-fite Biopharma's veterinary partner, Vetbiolix, reported positive results from a multicenter clinical study on osteoarthritis in dogs treated with Piclidenoson.
June 28, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Can-fite Biopharma's veterinary partner, Vetbiolix, reported positive results from a clinical study on osteoarthritis in dogs treated with Piclidenoson, which could boost investor confidence in CANF's product pipeline.
The positive clinical study results for Piclidenoson in treating osteoarthritis in dogs are likely to enhance investor confidence in Can-fite Biopharma's product pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100